Morgan Stanley Discount Zert BNTX.../ DE000MG3A1U9 /
29/08/2024 21:50:27 | Chg.+0.24 | Bid22:00:35 | Ask22:00:35 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
64.84EUR | +0.37% | - Bid Size: - |
- Ask Size: - |
BioNTech SE | - USD | 30/12/2025 | Call |
GlobeNewswire
16/08
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...
GlobeNewswire
14/08
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
01/08
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
30/07
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patie...
GlobeNewswire
22/07
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
GlobeNewswire
27/06
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...
GlobeNewswire
24/06
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT...
GlobeNewswire
01/06
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire
29/05
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GlobeNewswire
21/05
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire
21/05
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announ...
GlobeNewswire
17/05
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GlobeNewswire
17/05
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire
09/05
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update